{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:48:52Z","timestamp":1789663732211,"version":"4.0.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ejim.2017.05.012","type":"journal-article","created":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T09:31:37Z","timestamp":1495272697000},"page":"16-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Progress in the contemporary management of hemophilia: The new issue of patient aging"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1915-3897","authenticated-orcid":false,"given":"Pier Mannuccio","family":"Mannucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Iacobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2017.05.012_bb0005","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias \u2013 from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.05.012_bb0010","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"Berntorp","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.05.012_bb0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs","volume":"236","author":"Aledort","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2017.05.012_bb0025","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2008-1066024","article-title":"The phenotypic heterogeneity of severe hemophilia","volume":"34","author":"Jayandharan","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0030","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0035","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2009-04-217075","article-title":"Is VIII worse than IX?","volume":"114","author":"Makris","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2017.05.012_bb0040","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/hae.12133","article-title":"Is haemophilia B less severe than haemophilia A?","volume":"19","author":"Mannucci","year":"2013","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.ejim.2017.05.012_bb0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3324\/haematol.2015.133462","article-title":"Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A","volume":"101","author":"Melchiorre","year":"2016","journal-title":"Haematologica"},{"issue":"Suppl. 3","key":"10.1016\/j.ejim.2017.05.012_bb0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2516.2006.01281.x","article-title":"Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy","volume":"12","author":"van den Berg","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0055","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1365-2516.2003.00757.x","article-title":"The overall effectiveness of prophylaxis in severe haemophilia","volume":"9","author":"Panicker","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0070","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/203312a0","article-title":"Highpotency antihaemophilic factor concentrate prepared from cryoglobulin precipitate","volume":"203","author":"Pool","year":"1964","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2017.05.012_bb0075","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJM196512302732701","article-title":"Production of high-potency concentrates of antihaemophilic globulin in a closedbag system","volume":"273","author":"Pool","year":"1965","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2017.05.012_bb0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2017.05.012_bb0085","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/312330a0","article-title":"Expression of active human factor VIII from recombinant DNA clones","volume":"312","author":"Wood","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2017.05.012_bb0090","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM198901193200307","article-title":"Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia","volume":"320","author":"White","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.05.012_bb0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(88)92288-X","article-title":"Virus safety of solvent\/detergent-treated antihaemophilic factor concentrate","volume":"2","author":"Horowitz","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.05.012_bb0100","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1046\/j.1537-2995.1999.39111160.x","article-title":"The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1","volume":"39","author":"Tabor","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.ejim.2017.05.012_bb0105","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1160\/TH07-10-0593","article-title":"Recombinant clotting factors","volume":"99","author":"Pipe","year":"2008","journal-title":"Thromb Haemost"},{"issue":"8044","key":"10.1016\/j.ejim.2017.05.012_bb0110","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","article-title":"Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder","volume":"2","author":"Brackmann","year":"1977","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2017.05.012_bb0115","first-page":"30","article-title":"Immune tolerance for the treatment of factor VIII inhibitors\u2014twenty years' \u2018bonn protocol\u2019","volume":"70","author":"Brackmann","year":"1996","journal-title":"Vox Sang"},{"issue":"6","key":"10.1016\/j.ejim.2017.05.012_bb0120","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejim.2017.05.012_bb0125","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","article-title":"Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS study group","volume":"102","author":"Gringeri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2017.05.012_bb0130","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","article-title":"The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO","volume":"22","author":"Collins","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0135","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A","volume":"12","author":"Coyle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ejim.2017.05.012_bb0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejim.2017.05.012_bb0145","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2017.05.012_bb0150","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0155","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejim.2017.05.012_bb0160","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ejim.2017.05.012_bb0165","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2017.05.012_bb0175","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1538-7836.2006.01808.x","article-title":"Mortality and causes of death in patients with hemophilia, 1992\u20132001: a prospective cohort study","volume":"4","author":"Plug","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 4","key":"10.1016\/j.ejim.2017.05.012_bb0180","first-page":"s77","article-title":"Present and future challenges in the treatment of haemophilia: a clinician's perspective","volume":"11","author":"Mannucci","year":"2013","journal-title":"Blood Transfus"},{"key":"10.1016\/j.ejim.2017.05.012_bb0200","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/MBC.0000000000000225","article-title":"Rationale for individualizing hemophilia care","volume":"26","author":"Sorensen","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.ejim.2017.05.012_bb0205","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/jth.12202","article-title":"Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) [published correction appears in J Thromb Haemost. 2014;12:119\u2013122.]","volume":"11","author":"Manco-Johnson","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0210","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.05.012_bb0215","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.ejim.2017.05.012_bb0220","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1365-2516.2003.00817.x","article-title":"On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome","volume":"9","author":"Steen Carlsson","year":"2003","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.ejim.2017.05.012_bb0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2516.2000.00358.x","article-title":"Epidemiological survey of the orthopedic status of severe haemophilia A and B patients in France","volume":"6","author":"Molho","year":"2000","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0240","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2516.2004.01036.x","article-title":"A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia","volume":"10","author":"Ahnstrom","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0245","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1046\/j.1365-2516.2002.00694.x","article-title":"Prophylactic treatment for severe haemophilia: comparison of an intermediate dose to a high-dose regimen","volume":"8","author":"Fischer","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0250","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.05.012_bb0255","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2009.02191.x","article-title":"Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A","volume":"16","author":"Bjorkman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0260","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe hemophilia A: interim results from the first 5years of the Canadian Hemophilia Primary Prophylaxis Study","volume":"4","author":"Feldman","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0265","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/jth.12113","article-title":"Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study","volume":"11","author":"Hilliard","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2017.05.012_bb0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2516.9.s1.4.x","article-title":"Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective","volume":"9","author":"Bjorkman","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0275","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1538-7836.2010.03757.x","article-title":"Comparative pharmacokinetics of plasma and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age related differences and implications for dose tailoring","volume":"8","author":"Bjorkman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0280","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/hae.12438","article-title":"Considerations in individualizing prophylaxis in patients with hemophilia A","volume":"20","author":"Valentino","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0285","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","volume":"10","author":"Valentino","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0290","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH14-10-0826","article-title":"Participants, on behalf of the EUHASS. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project","volume":"113","author":"Fischer","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0295","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/jth.12335","article-title":"Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression","volume":"11","author":"Xi","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0300","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0305","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1055\/s-0038-1649954","article-title":"Haemophilia A: mutation type determines risk of inhibitor formation","volume":"74","author":"Schwaab","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0310","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2017.05.012_bb0315","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-2516.1998.0146c.x","article-title":"Inhibitors occur more frequently in African-American and Latino haemophiliacs","volume":"4","author":"Aledort","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0320","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0325","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2005-04-1371","article-title":"Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A","volume":"107","author":"Goudemand","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2017.05.012_bb0330","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2516.2006.01418.x","article-title":"Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A","volume":"13","author":"Chalmers","year":"2007","journal-title":"Haemophilia"},{"issue":"Suppl. 2","key":"10.1016\/j.ejim.2017.05.012_bb0335","first-page":"148","article-title":"Plasma-derived factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A: report of the FranceCoag Network","volume":"13","author":"Goudemand","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2017.05.012_bb0340","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.05.012_bb0345","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1182\/blood-2009-07-215665","article-title":"How I treat age-related morbidities in elderly persons with hemophilia","volume":"114","author":"Mannucci","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2017.05.012_bb0350","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.2009.07613.x","article-title":"Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs: a review of 116 procedures at a single institution","volume":"145","author":"Solimeno","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2017.05.012_bb0355","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s00198-014-2773-7","article-title":"Bone mineral density in men and children with haemophilia A and B: a systematic review and metaanalysis","volume":"25","author":"Paschou","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ejim.2017.05.012_bb0360","article-title":"Management of cardiovascular disease in aging persons with haemophilia","volume":"37","author":"Schutgens","year":"2017","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.ejim.2017.05.012_bb0365","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2016.02.001","article-title":"Understanding cardiovascular risk in hemophilia: a step towards prevention and management","volume":"140","author":"Sousos","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2017.05.012_bb0370","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/hae.12445","article-title":"Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe","volume":"20","author":"Schutgens","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0375","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1468-1293.2007.00534.x","article-title":"European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV","volume":"9","author":"Lundgren","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.ejim.2017.05.012_bb0380","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1351-8216.2003.00821.x","article-title":"Renal disease among males with haemophilia","volume":"9","author":"Kulkarni","year":"2003","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.ejim.2017.05.012_bb0385","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1586\/14737175.6.11.1643","article-title":"Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal","volume":"6","author":"Davies","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.ejim.2017.05.012_bb0390","doi-asserted-by":"crossref","DOI":"10.1111\/hae.13214","article-title":"Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study","author":"Witkop","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0395","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/hae.12526","article-title":"Managing chronic pain in adults with haemophilia: current status and call to action","volume":"21","author":"Humphries","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0400","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejim.2017.05.012_bb0405","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1345\/aph.1D252","article-title":"Measurement, correlates, and health outcomes of medication adherence among seniors","volume":"38","author":"Vik","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejim.2017.05.012_bb0410","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1532-5415.2011.03772.x","article-title":"Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans","volume":"60","author":"Marcum","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ejim.2017.05.012_bb0415","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.amjopharm.2010.06.003","article-title":"A pharmacoepidemiologic study of community-dwelling, disabled older women: factors associated with medication use","volume":"8","author":"Crenstil","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.ejim.2017.05.012_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146811","article-title":"Association between Potentially Inappropriate Medication (PIM) use and risk of hospitalization in older adults: an observational study based on routine data comparing PIM use with use of PIM alternatives","volume":"11","author":"Endres","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2017.05.012_bb0425","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(07)61092-7","article-title":"The challenge of managing drug interactions in elderly people","volume":"370","author":"Mallet","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.05.012_bb0430","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.clinthera.2006.08.006","article-title":"Clinically important drug-disease interactions and their prevalence in older adults","volume":"28","author":"Lindblad","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2017.05.012_bb0435","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/pds.2116","article-title":"Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population","volume":"20","author":"Jyrkka","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejim.2017.05.012_bb0440","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.05.012_bb0445","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"issue":"Suppl. 4","key":"10.1016\/j.ejim.2017.05.012_bb0450","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/hae.12411","article-title":"Current status of haemophilia gene therapy","volume":"20","author":"High","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2017.05.012_bb0455","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2017.05.012_bb0460","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/hgtb.2014.093","article-title":"Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery","volume":"25","author":"Wang","year":"2014","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.ejim.2017.05.012_bb0465","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/mt.2010.290","article-title":"A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of hemophilia A","volume":"19","author":"Matsui","year":"2011","journal-title":"Mol Ther"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517302108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517302108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T07:15:31Z","timestamp":1719213331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620517302108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":85,"alternative-id":["S0953620517302108"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2017.05.012","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in the contemporary management of hemophilia: The new issue of patient aging","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2017.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}